Diferencia entre revisiones de «Glyburide»
(Creation of page) |
|||
| (No se muestran 2 ediciones intermedias de 2 usuarios) | |||
| Línea 11: | Línea 11: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Safety/efficacy not established in pediatric patients | |||
==Special Populations== | ==Special Populations== | ||
| Línea 63: | Línea 63: | ||
==See Also== | ==See Also== | ||
[[Diabetes Medications]] | |||
==References== | ==References== | ||
| Línea 69: | Línea 69: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Endocrinology]] | |||
Revisión actual - 20:16 22 sep 2019
Administration
- Type: Sulfonylurea
- Dosage Forms: Tab: 1.25mg, 2.5 mg, 5 mg
- Routes of Administration: Oral
- Common Trade Names: DiaBeta, Micronase
Adult Dosing
Diabetes mellitus, Type 2
- 1.25-20 mg/day PO divided qd-bid
- Max: 20mg/day
Pediatric Dosing
Safety/efficacy not established in pediatric patients
Special Populations
- Pregnancy Rating: C
- Lactation risk: Caution advised while breastfeding
Renal Dosing
- Adult:
- CrCl <50: Avoid Use
- Pediatric:
- No current guidelines
Hepatic Dosing
- Adult:
- Start at 1.25 mg qd
- Pediatric:
- No current guidelines
Contraindications
- Allergy to class/drug
- CrCl < 50
- DKA
- Diabetes mellitus, type 1
Adverse Reactions
Serious
- Exfoliative dermatitis
- Erythema multiforme
- Hypoglycemia
- Cholestatic jaundice
- Hepatitis
- Aplasic anemia, hemolytic anemia, pancytopenia, thrombocytopenia
- Hyponatremia, SIADH
- Disulfiram-like rxn
Common
Pharmacology
- Half-life: 10h
- Metabolism: Liver; CYP2C9 substrate
- Excretion: Bile 50%, Urine 50%
Mechanism of Action
- Stimulates pancreatic islet beta cell insulin release